Anal canal cancer: biology and therapy

Bibliography

• Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997;337(19):1350-8
   PubMed Web of Science ®Google Scholar
• Daling JR, Weiss NS, Klopfenstein LL, et al. Correlates of homosexual behavior and the incidence of anal cancer. JAMA 1982;247(14):1988-90
   PubMedGoogle Scholar
• Melbye M, Coté TR, Kessler L, et al. High incidence of anal cancer among AIDS patients. The AIDS/Cancer Working Group. Lancet 1994;343(8898):636-9
   PubMedGoogle Scholar
• Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 1986;58(3):611-16
   PubMed Web of Science ®Google Scholar
• Schwartz LM, Castle PE, Follansbee S, et al. Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men. J Infect Dis 2013;208(11):1768-75
   PubMedGoogle Scholar
• Connell WR, Sheffield JP, Kamm MA, et al. Lower gastrointestinal malignancy in Crohn's disease. Gut 1994;35(3):347-52
   PubMed Web of Science ®Google Scholar
• Grulich AE, Poynten IM, Machalek DA, et al. The epidemiology of anal cancer. Sex Health 2012;9(6):504-8
   PubMed Web of Science ®Google Scholar
• Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer 2010;116(17):4007-13
   PubMed Web of Science ®Google Scholar
• Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365(17):1576-85
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP). 2011. MMWR Morb Mortal Wkly Rep 2011;60(50):1705-8
   PubMedGoogle Scholar
• Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348(9034):1049-54
   PubMed Web of Science ®Google Scholar
• Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010;102(7):1123-8
   PubMed Web of Science ®Google Scholar
• Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15(5):2040-9
   PubMed Web of Science ®Google Scholar
• Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14(9):2527-39
   PubMed Web of Science ®Google Scholar
• Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299(16):1914-21
   PubMed Web of Science ®Google Scholar
• Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 2012;30(35):4344-51
   PubMed Web of Science ®Google Scholar
• James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol 2013;14(6):516-24
   PubMed Web of Science ®Google Scholar
• Ben-Josef E, Moughan J, Ajani JA, et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol 2010;28(34):5061-6
   PubMed Web of Science ®Google Scholar
• Fyles A, Keane TJ, Barton M, Simm J. The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 1992;25(4):273-9
   PubMed Web of Science ®Google Scholar
• Peiffert D, Tournier-Rangeard L, Gérard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 2012;30(16):1941-8
   PubMed Web of Science ®Google Scholar
• Menkarios C, Azria D, Laliberté B, et al. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol 2007;2:41
   PubMed Web of Science ®Google Scholar
• Bazan JG, Hara W, Hsu A, et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011;117(15):3342-51
   PubMed Web of Science ®Google Scholar
• Pepek JM, Willett CG, Wu QJ, et al. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys 2010;78(5):1413-19
   PubMed Web of Science ®Google Scholar
• Mitchell MP, Abboud M, Eng C, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol 2013. [Epub ahead of print]
   Google Scholar
• Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013;86(1):27-33
   PubMed Web of Science ®Google Scholar
• Benson AB III, Arnoletti JP, Bekaii-Saab T, et al. Anal carcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10(4):449-54
   PubMed Web of Science ®Google Scholar
• Krengli M, Milia ME, Turri L, et al. FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol 2010;5:10
   PubMedGoogle Scholar
• Mistrangelo M, Pelosi E, Bellò M, et al. Role of positron emission tomography-computed tomography in the management of anal cancer. Int J Radiat Oncol Biol Phys 2012;84(1):66-72
   PubMed Web of Science ®Google Scholar
• Bhuva NJ, Glynne-Jones R, Sonoda L, et al. To PET or not to PET? That is the question. Staging in anal cancer. Ann Oncol 2012;23(8):2078-82
   PubMedGoogle Scholar
• Sveistrup J, Loft A, Berthelsen AK, et al. Positron emission tomography/computed tomography in the staging and treatment of anal cancer. Int J Radiat Oncol Biol Phys 2012;83(1):134-41
   PubMed Web of Science ®Google Scholar
• Saboo SS, Zukotynski K, Shinagare AB, et al. Anal carcinoma: FDG PET/CT in staging, response evaluation, and follow-up. Abdom Imaging 2013;38(4):728-35
   PubMedGoogle Scholar
• Vercellino L, Montravers F, de Parades V, et al. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma. Int J Colorectal Dis 2011;26(2):201-10
   PubMed Web of Science ®Google Scholar
• Zhang J, Martins CR, Fansler ZB, et al. DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma. Clin Cancer Res 2005;11(18):6544-9
   PubMedGoogle Scholar
• Patel H, Polanco-Echeverry G, Segditsas S, et al. Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma. Int J Cancer 2007;121(12):2668-73
   PubMedGoogle Scholar
• Nilsson PJ, Lenander C, Rubio C, et al. Prognostic significance of Cyclin A in epidermoid anal cancer. Oncol Rep 2006;16(3):443-9
   PubMedGoogle Scholar
• Bruland O, Fluge O, Immervoll H, et al. Gene expression reveals two distinct groups of anal carcinomas with clinical implications. Br J Cancer 2008;98(7):1264-73
   PubMed Web of Science ®Google Scholar
• Lampejo T, Kavanagh D, Clark J, et al. Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer 2010;103(12):1858-69
   PubMed Web of Science ®Google Scholar
• Alvarez G, Perry A, Tan BR, Wang HL. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol 2006;19(7):942-9
   PubMed Web of Science ®Google Scholar
• Gervaz P, Hahnloser D, Wolff BG, et al. Molecular biology of squamous cell carcinoma of the anus: a comparison of HIV-positive and HIV-negative patients. J Gastrointest Surg 2004;8(8):1024-30; discussion 1031
   PubMed Web of Science ®Google Scholar
• Siegel E, Eschrich S, Winter K, et al. Epigenomic profiling of anal cancer: Does size matter?-an RTOG 98-11 specimen study. International Anal Neoplasia Society Annual Meeting;San Francisco, CA; 2013
   Google Scholar
• Ajani JA, Wang X, Izzo JG, et al. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci 2010;55(4):1098-105
   PubMed Web of Science ®Google Scholar